Literature DB >> 11350607

Maturation of macrophages from peripheral blood monocytes in Kawasaki disease: immunocytochemical and immunoelectron microscopic study.

S Ariga1, M Koga, M Takahashi, T Ishihara, T Matsubara, S Furukawa.   

Abstract

Kawasaki disease (KD) is regarded as a cytokine-associated disorder. Despite intensive investigation into the etiology of KD, this remains unclear, although monocytes and macrophages are thought to play an important role. We examined peripheral blood monocytes using a monoclonal antibody, PM-2K, which recognizes mature macrophages but not monocytes. This study was conducted in 12 patients with KD, three patients with sepsis and 12 control subjects. Approximately 8% of whole peripheral blood monocytes from patients with acute KD were observed to be PM-2K positive. Approximately 15-20% of peripheral blood CD14+ monocytes from these patients were positive for PM-2K antibody (as determined by immunoelectron microscopy). PM-2K-positive monocytes had significantly fewer numbers of intracytoplasmic peroxidase-positive granules than monocytes from control subjects. In contrast, PM-2K-negative monocytes from patients with acute KD had a significantly greater number of peroxidase-positive granules in the cytoplasm than in those from controls. Monocytes from patients with sepsis displayed PM-2K immunocytochemical staining, similar to that in monocytes from patients with KD. These results suggest that during the acute stage of KD, monocytes partly differentiate into macrophages in the peripheral circulation.

Entities:  

Mesh:

Year:  2001        PMID: 11350607     DOI: 10.1046/j.1440-1827.2001.01202.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

Review 1.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

2.  Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.

Authors:  Haruyuki Makata; Takashi Ichiyama; Ryutaro Uchi; Tsuyoshi Takekawa; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

3.  Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages.

Authors:  Takashi Ichiyama; Yoshiko Ueno; Masanari Hasegawa; Akihiro Niimi; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-25       Impact factor: 3.000

Review 4.  An Update on Cardiovascular Risk Factors After Kawasaki Disease.

Authors:  Yuan-Yuan Zeng; Min Zhang; Syeun Ko; Feng Chen
Journal:  Front Cardiovasc Med       Date:  2021-04-16

Review 5.  Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.

Authors:  Ganesh Athappan; Seth Gale; Thirumalaikolundusubramanian Ponniah
Journal:  Cardiovasc J Afr       Date:  2009 Jul-Aug       Impact factor: 1.167

6.  Altered pattern of monocyte differentiation and monocyte-derived TGF-β1 in severe asthma.

Authors:  Chih-Hsing Hung; Chin-Chou Wang; Jau-Ling Suen; Chau-Chyun Sheu; Chang-Hung Kuo; Wei-Ting Liao; Yi-Hsin Yang; Chao-Chien Wu; Sum-Yee Leung; Ruay-Sheng Lai; Chi-Cheng Lin; Yu-Feng Wei; Chong-Yeh Lee; Ming-Shyan Huang; Shau-Ku Huang
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.